|17th September 2020||Suma Krishnan||1,126||Open or private sale||$47.29||$53,248.31|
|17th September 2020||Suma Krishnan||7,437||Open or private sale||$46.63||$346,813.34|
|17th September 2020||Suma Krishnan||10,594||Open or private sale||$46.09||$488,296.53|
|16th September 2020||Suma Krishnan||9,749||Open or private sale||$46.24||$450,821.06|
|16th September 2020||Suma Krishnan||5,142||Open or private sale||$46.85||$240,895.50|
|15th September 2020||Suma Krishnan||14,435||Open or private sale||$46.21||$667,031.25|
|15th September 2020||Suma Krishnan||1,517||Open or private sale||$47.15||$71,523.21|
|29th June 2020||Antony A Riley||2,000||Open or private purchase||$14.11||$28,220.00|
|26th June 2020||Antony A Riley||4,700||Open or private purchase||$14.52||$68,225.20|
|15th June 2020||Suma Krishnan||8,652||Open or private sale||$42.24||$365,426.74|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Krystal Biotech, Inc. engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform.